CTA
NKTR icon

Carillon Tower Advisers’s Nektar Therapeutics NKTR Stock Holding History

Carillon Tower Advisers’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-21,185
Closed -$19.4M – 469
2018
Q3 		$19.4M Sell
21,185
-46,635
-69% -$39.8M 0.14% 240
2018
Q2 		$49.7M Buy
67,820
+19,792
+41% +$22.8M 0.39% 80
2018
Q1 		$71.2M Hold
48,028
– – 0.55% 34
2017
Q4 		$43K Buy
+48,028
New +$28.4M 0.46% 68

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Carillon Tower Advisers's NKTR Position: Q4 2018 in Review

Carillon Tower Advisers sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 21,185 shares — an estimated $19.4M sold.

Carillon Tower Advisers first reported a position in NKTR in Q4 2017 and held it in 4 quarters. The position peaked at $71.2M in Q1 2018. 342 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Carillon Tower Advisers reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Carillon Tower Advisers sold 21,185 Nektar Therapeutics shares in Q4 2018, an estimated $19.4M.
  • Carillon Tower Advisers first reported a position in Nektar Therapeutics in Q4 2017 and held it in 4 quarters.
  • Carillon Tower Advisers's Nektar Therapeutics position peaked at $71.2M in Q1 2018.
  • 342 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Carillon Tower Advisers's 13F filing for Q4 2018, filed 13 Feb 2019.